June 15th 2025
The report highlights clinical successes, innovation, research, and patient outcomes.
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Practical Approaches to Modern Dry Eye Treatment and Management
June 25, 2025
Register Now!
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)
View More
Retina Specialists: Join us in Long Beach
July 31, 2025 - August 2, 2025
Register Now!
SimulatED™: Pioneering Treat-and-Extend Therapy—The Impact of Early Application
View More
Rapid Reviews in Retina™: Emerging Updates from Summer 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
3rd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
September 6, 2025
Register Now!
Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C/D
View More
EyeCon 2025
September 26-27, 2025
Register Now!
Optometrists: Earn COPE CE Credits in Portland or Virtually
October 16-17, 2025
Register Now!
Join us at The Ophthalmology Meeting in Orlando this October
October 18, 2025
Register Now!
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
Community Practice Connections™: Transforming Treatment in nAMD, DME, and DR – Keeping an Eye on Optimal Outcomes
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Expert Perspectives on Technological Advances in Cataract Surgery
View More
Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy
View More
Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy
View More
(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes
View More
Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs
View More
(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention
View More
Ocugen announces positive clinical study update from the phase 1/2 trial of OCU400
September 15th 2023According to the company, the clinical study update suggests continued positive trends in best-corrected visual acuity and multi-luminance mobility testing as well as positive trends in low-luminance visual acuity among treated eyes.
What retina specialists want you to know about neovascular AMD and DME therapies: 10 top takeaways
September 15th 2023A panel of esteemed retina specialists recently delved into innovative therapies for neovascular age-related macular degeneration and diabetic macular edema, focusing on personalized treatment, telemedicine, and the ongoing quest for advancements.
OWL Leadership Summit 2023: Navigating ophthalmic leadership challenges and embracing diversity
September 14th 2023The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.
Opus Genetics doses first patient in Phase 1/2 trial of OPGx-LCA5 in patients diagnosed with LCA5
September 12th 2023According to the company, OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies.
EyeSouth Partners has partnered with Retina and Vitreous of Texas in Houston
September 5th 2023EyeSouth Partners has partnered with Retina and Vitreous of Texas, a retina-only practice in Houston, Texas. The company’s current network encompasses 38 practices and over 300 doctors who deliver medical and surgical eye care services across more than 180 locations.
Orbis celebrates 20 Years of Cybersight telemedicine platform, new app
September 5th 2023According to the company, the tool provides free access to training and mentors for eye care professionals in areas with the greatest need, and the new Cybersight mobile app expands access for eye care professionals through offline functionality.
UC Irvine researchers discover a nanobody which may lead to treatment for retinitis pigmentosa
September 1st 2023According to the university, a special antibody that is derived from llamas, called a nanobody, can stop the misfolding and the activation of Rhodopsin, a molecule whose mutations can lead to blindness.
EMA approves Clinical Trial Application for retinitis pigmentosa therapy from ViGeneron
August 23rd 2023European Medicines Agency issued approval for a Clinical Trial Application of its new gene therapy, VG901, which uses an adeno-associated virus vector to treat CNGA1-associated retinitis pigmentosa.
AI-generated ophthalmic references and abstracts: Proceed with caution
August 18th 2023Clinicians should be alert to the fact that while artificial intelligence (AI) is capable of generating ideas and references, it is crucial to thoroughly vet and fact-check any medical research content that AI produces.